| Original language | English |
|---|---|
| Article number | 00467-2021 |
| Journal | ERJ Open Research |
| Volume | 7 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Oct 2021 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: ERJ Open Research, Vol. 7, No. 4, 00467-2021, 01.10.2021.
Research output: Contribution to journal › Letter › Academic › peer-review
TY - JOUR
T1 - Granulomatous-lymphocytic interstitial lung disease
T2 - An international research prioritisation
AU - Hurst, John R.
AU - Abbas, S. Hamza
AU - Bintalib, Heba M.
AU - Alfaro, Tiago M.
AU - Baumann, Ulrich
AU - Burns, Siobhan O.
AU - Condliffe, Alison
AU - Davidsen, Jesper R.
AU - Fevang, Børre
AU - Gennery, Andrew R.
AU - Haerynck, Filomeen
AU - Jacob, Joseph
AU - Jolles, Stephen
AU - Lamers, Olivia
AU - Bergeron, Anne
AU - Malphettes, Marion
AU - Meignin, Véronique
AU - Milito, Cinzia
AU - Milota, Tomas
AU - Pergent, Martine
AU - Prasse, Antje
AU - Quinti, Isabella
AU - Renzoni, Elisabetta
AU - Sediva, Anna
AU - Stolz, Daiana
AU - Smits, Bas
AU - Strauss, Friedolin
AU - Van De Ven Annick, A. J.M.
AU - Van Montfrans, Joris
AU - Warnatz, Klaus
N1 - Funding Information: Conflict of interest: J.R. Hurst reports grants, personal fees and nonfinancial support from pharmaceutical companies that make medicines to treat respiratory and immunological diseases outside the submitted work. S.M. Abbas has nothing to disclose. H.M. Bintalib has nothing to disclose. T.M. Alfaro has nothing to disclose. U. Baumann has nothing to disclose. S.O. Burns reports personal fees from CSL Behring, Baxalta US Inc., Biotest, the European Union, the National Institute of Health Research, UCLH and GOSH/Institute of Child Health Biomedical Research Centers, and CSL Behring, outside the submitted work. A. Condliffe has nothing to disclose. J.R. Davidsen has nothing to disclose. B. Fevang has nothing to disclose. A.R. Gennery has nothing to disclose. F. Haerynck has nothing to disclose. J. Jacob reports personal fees from Boehringer Ingelheim, Roche and GlaxoSmithKline, outside the submitted work. S. Jolles has nothing to disclose. O. Lamers has nothing to disclose. A. Bergeron reports grants from SOS Oxygene, personal fees from Takeda, and personal fees from AstraZeneca, Pfizer, MSD, Gilead and Enanta, outside the submitted work. M. Malphettes has nothing to disclose. V. Meignin has nothing to disclose. C. Milito has nothing to disclose. T. Milota has nothing to disclose. M. Pergent has nothing to disclose. A. Prasse reports personal fees from Boehringer Ingelheim, Roche, Novartis, Chiesi, Pliant and AstraZeneca outside the submitted work. I. Quinti has nothing to disclose. E. Renzoni reports grants from Boehringer Ingelheim, and lecture fees from Boehringer Ingelheim and Roche, outside the submitted work. A. Sediva has nothing to disclose. D. Stolz reports grants from AstraZeneca AG, Curetis AG and Boston Scientific, and payment for lectures and/or advisory boards from AstraZeneca AG, Novartis AG, GSK AG, Roche AG, Zambon, Pfizer, Schwabe Pharma AG, Vifor AG, Chiesi AG and MSD, outside the submitted work. B. Smits has nothing to disclose. F. Strauss has nothing to disclose. A.A.J.M. van de Ven has nothing to disclose. J. van Montfrans reports having participated in an advisory board for Takeda during the conduct of the study. K. Warnatz reports grants from Bristol Myers Squibb outside the submitted work. Funding Information: Support statement: This study was supported by the European Respiratory Society. Funding information for this article has been deposited with the Crossref Funder Registry.
PY - 2021/10/1
Y1 - 2021/10/1
UR - https://www.scopus.com/pages/publications/85123515624
U2 - 10.1183/23120541.00467-2021
DO - 10.1183/23120541.00467-2021
M3 - Letter
AN - SCOPUS:85123515624
SN - 2312-0541
VL - 7
JO - ERJ Open Research
JF - ERJ Open Research
IS - 4
M1 - 00467-2021
ER -